$1,318.00
The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Treatment of hypogonadism in females
8 Treatment of hypogonadism in males
9 EPIDEMIOLOGY
10 MARKETED DRUGS
15 PIPELINE DRUGS
19 KEY UPCOMING EVENTS
20 PROBABILITY OF SUCCESS
21 LICENSING AND ASSET ACQUISITION DEALS
21 Lipocine Partners With Antares For US Commercialization Of Tlando
22 REVENUE OPPORTUNITY
24 CLINICAL TRIAL LANDSCAPE
25 Sponsors by status
26 Sponsors by phase
28 BIBLIOGRAPHY
29 APPENDIX
LIST OF FIGURES
15 Figure 1: Overview of pipeline drugs for hypogonadism in the US
15 Figure 2: Pipeline drugs for hypogonadism, by company
16 Figure 3: Pipeline drugs for hypogonadism, by drug type
16 Figure 4: Pipeline drugs for hypogonadism, by classification
19 Figure 5: Key upcoming events in hypogonadism
20 Figure 6: Probability of success in the endocrine-other pipeline
24 Figure 7: Clinical trials in hypogonadism
24 Figure 8: Top 10 drugs for clinical trials in hypogonadism
25 Figure 9: Top 10 companies for clinical trials in hypogonadism
25 Figure 10: Trial locations in hypogonadism
26 Figure 11: Hypogonadism trials status
27 Figure 12: Hypogonadism trials sponsors, by phase
LIST OF TABLES
11 Table 1: Marketed drugs for hypogonadism
17 Table 2: Pipeline drugs for hypogonadism in the US
22 Table 3: Historical global sales, by drug ($m), 2016–20
23 Table 4: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!